NCT06302270

Brief Summary

Observational study on women with Cystic Fibrosis treated with CFTR modulators during pregnancy and postpartum and their children. Registration on maternal health parameters and effects of CFTR-modulators in the newborn infant as well as effects of exposure through mother's own milk.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
75

participants targeted

Target at P50-P75 for all trials

Timeline
152mo left

Started Mar 2024

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress16%
Mar 2024Jan 2039

First Submitted

Initial submission to the registry

March 4, 2024

Completed
4 days until next milestone

First Posted

Study publicly available on registry

March 8, 2024

Completed
7 days until next milestone

Study Start

First participant enrolled

March 15, 2024

Completed
9.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 31, 2034

Expected
5 years until next milestone

Study Completion

Last participant's last visit for all outcomes

January 31, 2039

Last Updated

March 8, 2024

Status Verified

March 1, 2024

Enrollment Period

9.9 years

First QC Date

March 4, 2024

Last Update Submit

March 4, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Health effects in the newborn infant

    6 years

Study Arms (1)

mother-infant dyads

Eligibility Criteria

AgeUp to 50 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)
Sampling MethodProbability Sample
Study Population

Woman with cystic fibrosis who is pregnant and treated with Kaftrio and her newborn infant

You may qualify if:

  • Woman with cystic fibrosis who is pregnant and treated with Kaftrio. Newborn infant to the above mentioned woman

You may not qualify if:

  • none

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Stockholm CF center

Stockholm, Sweden

RECRUITING

Biospecimen

Retention: SAMPLES WITHOUT DNA

plasma and breastmilk

MeSH Terms

Conditions

Cystic Fibrosis

Condition Hierarchy (Ancestors)

Pancreatic DiseasesDigestive System DiseasesLung DiseasesRespiratory Tract DiseasesGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesInfant, Newborn, Diseases

Central Study Contacts

Terezia Pinzikova

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 4, 2024

First Posted

March 8, 2024

Study Start

March 15, 2024

Primary Completion (Estimated)

January 31, 2034

Study Completion (Estimated)

January 31, 2039

Last Updated

March 8, 2024

Record last verified: 2024-03

Data Sharing

IPD Sharing
Will not share

NO plan to share individual data. Not allowed.

Locations